

# ExoDx™ PROSTATE TEST - PATIENT REPORT

#### **Patient Information**

**Patient Name:** Exosome Test

**Patient DOB:** Jan 30, 1948

Sex: Male

0

**Exosome ID:** 

Oct1-1

**Collection Date:** 

09/29/2021

#### **Order Information**

**Specimen Receipt Date:** 

10/01/2021

**Exosome Site ID:** 

EXO1006

**Ordering Physician:** 

**Bob McDoctorson** 266 Second Ave.

Waltham, MA- Massachusetts

### **Test Results**


The ExoDx Prostate Test, or EPI is a risk assessment tool. A score below 15.6 indicates a lower risk of high-grade prostate cancer (≥GG2) with a sensitivity of 92.0% and a negative predictive value (NPV) of 91.3%. A score above 15.6 indicates an increasing risk of high-grade prostate cancer. This score should be used with other clinical factors to determine whether to proceed with a tissue biopsy.

**Exosome, your ExoDx Prostate** Test score is 32.4

\*Graphic is indicative of increased risk but not representative of a linear relationship, please refer to the bar graph and referenced data.

## **Test Description, Methods & Limitations**

Cut point 15.6



In three prospective studies with a combined total of 1212 men, the graph above shows the percentage of men within in each EPI range with high-grade prostate cancer. Margolis et al. Prostate Ca and Prostatic Diseases 2021

The ExoDx(TM) Prostate Test or EPI (ExoDx Prostate Intelliscore Test) is a non-DRE urine-based liquid biomarker test indicated for men 50 years of age and older with a PSA 2-10 ng/mL being considered for an initial prostate biopsy or repeat biopsy due to prior negative biopsy.



**Learn More About Test Methods, Supporting Publications and** Limitations

Report Approval Date (mm/dd/yyyy):

10/01/2021

Reported under the direction of:

Nicole Faulkner, PhD, FACMG

This Laboratory Developed Test was developed, and its performance characteristics determined by Exosome Diagnostics, Inc. The laboratory is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the U.S. Food and Drug Administration.  $@2022 \, Exosome \, Diagnostics, \, Inc. \, Exosome \, Diagnostics \, and \, ExoDx \, are \, registered \, and \, unregistered \, trademarks \, of \, Exosome \, Diagnostics, \, Inc. \, Diagnostics, \, Diagnostics,$ 

Increasing risk of HGPCA

100